SCHEMBL5329593

SCHEMBL5329593

COC(=O)c1ccc(-c2ccco2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.58
NPC1 O15118 1/20 0.55
TP53 P04637 1/20 0.55
RAB9A P51151 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
PTGS1 P23219 1/20 0.53
SLC6A4 P31645 1/20 0.53
SLC6A3 Q01959 1/20 0.53
PSMD14 O00487 1/20 0.52
CACNA1B Q00975 1/20 0.52
APBA1 Q02410 1/20 0.52
NR4A2 P43354 1/20 0.52
MEN1 O00255 2/20 0.51
POLB P06746 2/20 0.51
TSHR P16473 2/20 0.51
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
MAOB P27338 1/20 0.51
TAAR1 Q96RJ0 4/20 0.50
TNKS O95271 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14967250 0.82 KMT2A (0.55) KMT2ASLC6A4SLC6A3NR4A2MEN1
SCHEMBL3692629 0.80 MAPT (0.53) KMT2ASMN1; SMN2SLC6A4SLC6A3MEN1
SCHEMBL27623999 0.80 TAAR1 (0.55) KMT2ANPC1RAB9ASLC6A4SLC6A3
SCHEMBL2396285 0.79 KMT2A (0.54) KMT2ANPC1TP53RAB9ASMN1; SMN2
SCHEMBL4682626 0.78 KEAP1 (0.66) KMT2ATP53PTGS1MEN1POLB
SCHEMBL19387238 0.77 CA1 (0.70) KMT2ARAB9AMEN1TSHRKDM4E
Biphenyl Dimethyl Dicarboxylate SCHEMBL68521 0.77 CA1 (0.70) KMT2ARAB9AMEN1TSHRKDM4E
SCHEMBL16147858 0.77 TAAR1 (0.52) KMT2ANPC1RAB9ASLC6A4SLC6A3
SCHEMBL4964453 0.77 TAAR1 (0.57) KMT2ANPC1TP53RAB9ASMN1; SMN2
SCHEMBL27176217 0.76 AXL (0.58) KMT2ARAB9ASLC6A4SLC6A3CACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240299559-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2024-09-12 US disclosed
WO-2023069700-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2023-04-27 WO disclosed
US-20070259879-A1 Piperazine and piperidine biaryl derivatives TRIMERIS, INC. 2007-11-08 US disclosed
US-20070259879-A1 Piperazine and piperidine biaryl derivatives TRIMERIS, INC. 2007-11-08 US disclosed
US-20070259879-A1 Piperazine and piperidine biaryl derivatives TRIMERIS, INC. 2007-11-08 US disclosed
WO-2007103456-A2 PIPERAZINE AND PIPERIDINE BIARYL DERIVATIVES TRIMERIS, INC. (US) 2007-09-13 WO disclosed
WO-2007103456-A2 PIPERAZINE AND PIPERIDINE BIARYL DERIVATIVES TRIMERIS, INC. (US) 2007-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299559-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF CDK2, SKP2, CDK1 KMT2A 2021/4885NPC1 3502/4885TP53 38/4885
US-20070259879-A1 Piperazine and piperidine biaryl derivatives CYP3A5, CYP3A43, CCR5 KMT2A 1777/4885NPC1 723/4885TP53 1958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.